bioMérieux Invests Over 250 Million Euros in Isère to Produce BIOFIRE PCR Tests
The in vitro diagnostics group announces the creation of a new production unit in Isère for its Biofire PCR tests, with approximately 400 direct jobs expected and a planned operational start in 2030. This project aims to meet the growing diagnostic needs for infectious diseases in the European market.
bioMérieux is establishing a production unit at La Balme-les-Grottes (Isère) dedicated to manufacturing syndromic PCR tests from its Biofire range. These tests can identify the main causes of respiratory, blood, gastrointestinal, or meningeal infections within 15 to 60 minutes from a single sample.
The production will primarily target the European market and will complement the capabilities of the Salt Lake City site in the United States. According to Pierre Boulud, CEO of bioMérieux, syndromic tests account for nearly 40% of the group's revenue. This new unit aims to 'support long-term growth and strengthen the resilience of supply chains'.
Strengthening the Isère Site and Creating Jobs
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The La Balme-les-Grottes site, an industrial pillar of bioMérieux for over 40 years, currently employs about 600 collaborators. The new project is expected to generate around 400 direct jobs in the long term. Over the past few years, it has benefited from several strategic investments, including a microbiology research and development building and an internal production unit inaugurated in 2023 and 2024.
The project is part of a strategy of vertical integration for the group and consolidation of its industrial presence in France, particularly in the Auvergne-Rhône-Alpes region where bioMérieux has its historical roots.
A Project Designed According to Rigorous Environmental Standards
The new building will be located on an existing industrial brownfield site to limit soil sealing. Its design incorporates energy efficiency solutions with operations relying on 'almost entirely decarbonized' energy. Optimizing logistic flows to European customers is expected to prevent the emission of nearly 9,000 tons of CO2 per year compared to equivalent production overseas.
The project also includes solar panels, green roofs, permeable parking lots, sustainable management of outdoor spaces, rainwater recovery, and biodiversity preservation measures. The factory is scheduled to start operations in 2030.
SectorSanté · Vaccins et laboratoires de recherche›Équipements Médicaux
Context
Period
Period: 9M 2025
Guidance from the release
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
